U. Schmidt-Erfurth Et Al. , "Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study," OPHTHALMOLOGY , vol.118, no.5, pp.831-839, 2011
Schmidt-Erfurth, U. Et Al. 2011. Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study. OPHTHALMOLOGY , vol.118, no.5 , 831-839.
Schmidt-Erfurth, U., Eldem, B., Guymer, R., Korobelnik, J., Schlingemann, R. O., Axer-Siegel, R., ... Wiedemann, P.(2011). Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study. OPHTHALMOLOGY , vol.118, no.5, 831-839.
Schmidt-Erfurth, Ursula Et Al. "Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study," OPHTHALMOLOGY , vol.118, no.5, 831-839, 2011
Schmidt-Erfurth, Ursula Et Al. "Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study." OPHTHALMOLOGY , vol.118, no.5, pp.831-839, 2011
Schmidt-Erfurth, U. Et Al. (2011) . "Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study." OPHTHALMOLOGY , vol.118, no.5, pp.831-839.
@article{article, author={Ursula Schmidt-Erfurth Et Al. }, title={Efficacy and Safety of Monthly versus Quarterly Ranibizumab Treatment in Neovascular Age-related Macular Degeneration: The EXCITE Study}, journal={OPHTHALMOLOGY}, year=2011, pages={831-839} }